Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Table 4 Patient characteristics prior to third-line treatment with cabometyx

Characteristics at baseline	Cabozantinib (n = 16)
Age–median (Q1Q3), yr	68 (64-75)
Gender, n (%)
Male	15 (94)
Female	1 (6)
PS, n (%)
0	8 (50)
1	7 (44)
2	1 (6)
Macrovascular invasion, n (%)	6 (38)
Extrahepatic disease, n (%)	10 (62)
Child-Pugh class, n (%)
A	10 (62)
B	6 (38)
BCLC, n (%)
B	3 (19)
C	13 (81)
AFP, ng/mL, n (%)
< 400	8 (50)
≥ 400	8 (50)
Maximal tumor diameter, mm–median (Q1Q3)	60 (32-106)
Hemoglobin, g/dL–median (Q1Q3)	13.7 (11.4-14.7)
Platelet’s count (× 100/L)–median (Q1Q3)	159 (107-246)
Neutrophil count/L–median (Q1Q3)	4690 (3128-7463)
Lymphocyte count/L–median (Q1Q3)	1063 (783-1359)
Neutrophil–lymphocyte ratio, n (%)
≤ 3	3 (19)
> 3	13 (81)
CRP, mg/L–median (Q1Q3)	33 (7-78)
AST, IU/L–median (Q1Q3)	51 (33-76)
ALT, IU/L–median (Q1Q3)	29 (21-53)
GGT, IU/L–median (Q1Q3)	188 (111-323)
ALP, IU/L–median (Q1Q3)	162 (120-253)
Total bilirubin, μmol/L–median (Q1Q3)	15.9 (11.1-25.6)
Albumin, g/L–median (Q1Q3)	33.5 (27.9-39.2)
Creatinine, μmol/L–median (Q1Q3)	82 (56-91)
Prothrombin time, %–median (Q1Q3)	81 (70-92)

PS: Performance status; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-Glutamyl transpeptidase; ALP: Alkaline phosphatase.